Post on 04-Jul-2020
transcript
Workshop on the joint procurement of medical countermeasures – 29 April 2015
Access to High-Cost Medicines
Dirk Van den Steen
Healthcare Systems Unit
European Commission Directorate-General for Health and Consumers
European Commission Vision: To ensure accessible and affordable treatments for all EU citizens and to minimize unintended effects from current pricing systems in Member States, by improving cooperation and coordination at EU-level.
Access to Medicines: EU added value
Access to Medicines: EU added value
Commission Declaration: "[… the use of the joint procurement mechanism, developed by the Commission at the Council’s request to counteract cross-border health threats, was further explored. The range of medical countermeasures that can be procured through this mechanism was confirmed in December last year. The joint procurement mechanism may help to improve access to medicines at more balanced conditions from the pharmaceutical industry. …]"
http://ec.europa.eu/health/files/committee/73meeting/73plus/study_report.pdf
Problem Drivers?
http://ec.europa.eu/health/systems_performance_assessment/docs/erp_reimbursement_medicinal_products_en.pdf
Real-life Impacts?
TFEU: Article 168(7) of the Treaty, Member States are responsible for the definition of their health policies as well as for the organisation and delivery of health services. This includes measures regulating the prices of medicines and their inclusion in health insurance systems. But, Article 168(2) the Union shall encourage cooperation between the Member States.
EU level mandate
Commission Communication and Agenda for Action
Commission Communication and Agenda for Action
9
I would like you to focus on
working together with the
Commissioner For Internal Market,
Industry, Entrepreneurship and
SMEs to jointly develop EU policies
as regards medicines and
pharmaceutical products while
taking fully into account that
medicines are
not goods like any other.
• Objective to secure a high level of public health and innovation.
• Access to medicines and treatments is affordable.
• Medicines are safe and effective.
• Objective to provide support for a competitive industry that ensures that Europe continues to benefit from new medicines.
• Enhance the competitiveness of Europe’s pharmaceutical sector.
Initiatives on pricing
• Despite the limited competence, there is a growing impetus to discuss at the EU level.
• Links with the accessibility of medicinal care have been raised in a number of recent Council Conclusions.
• The Commission is fostering cooperation between Member States in order to find synergies.
• Overall goal to achieve better and enhanced cross-country coordination at EU level in the area of pharmaceutical pricing.
10
EU level discussions
11
Initiatives on pricing
• The Health Programme 2014-2020 to support the policy debate, build up a sound evidence base and explore possible policy avenues.
• A project grant to improve information sharing on the prices of medicinal products (expected to start in 2015 for a duration of 3 years).
• A study exploring alternative pricing approaches as well as related cooperation mechanisms in view of possible impacts, including on patient access (delivery by the end of 2015).
12
The challenge at hand: Prices affordable to all, combined
with free movement of goods?
13 http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf
14
Source of data Eurostat
Short Description Short Description is not available
UNIT Current prices, euro per capita
NA_ITEM Gross domestic product at market prices
GEO/TIME 2013
European Union (28 countries) 26.600 100
Luxembourg 83.100 312
Sweden 45.500 171
Denmark 45.100 170
Netherlands 38.300 144
Austria 38.100 143
Ireland 38.000 143
Finland 37.100 139
Belgium 35.600 134
Germany (until 1990 former territory of the FRG) 34.200 129
France 32.100 121
United Kingdom 31.500 118
Italy 26.500 100
Spain 22.500 85
Cyprus 21.000 79
Malta 17.900 67
Slovenia 17.500 66
Greece 16.500 62
Portugal 16.200 61
Czech Republic 15.000 56
Estonia 14.200 53
Slovakia 13.600 51
Lithuania 11.800 44
Latvia 11.600 44
Croatia 10.200 38
Hungary 10.200 38
Romania 7.200 27
Bulgaria 5.600 21
Poland NA NA
http://www.scb.se/Statistik/PR/PR0401/_documents/Pharmaceutical%20Products.pdf
15
Main Consideration for the JPA vis-à-vis access to medicines
How to address the issue of "price" under the JPA?
Can there be several JPAs for a given product, clustering Member States by purchasing capacity?
If so, what is an acceptable trade-off between getting
the lowest possible price by pooling market size
vs
he highest possible accessibility by differentiating price?
•
16
Thank you!
European Commission
Public Health information:
http://ec.europa.eu/health/systems_performance_assessment/policy/index_en.htm
http://ec.europa.eu/europe2020/making-it-happen/index_en.htm